UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

The challenge of ventilator-associated pneumonia diagnosis in COVID-19 patients

Critical care (London, England), 2020-06, Vol.24 (1), p.289-289, Article 289

2020

Volltextzugriff (PDF)

Co-infections in COVID-19 critically ill and antibiotic management: a prospective cohort analysis

Critical care (London, England), 2020-07, Vol.24 (1), p.410-410, Article 410

2020

Volltextzugriff (PDF)

Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]

Critical care (London, England), 2004-04, Vol.8 (2), p.R82-R90

2004

Volltextzugriff (PDF)

Determinants of long-term outcome in ICU survivors: results from the FROG-ICU study

Critical care (London, England), 2018-01, Vol.22 (1), p.8-8, Article 8

2018

Volltextzugriff (PDF)

Beyond antibiotics in severe community-acquired pneumonia: the role and rationale for tissue factor pathway inhibition

Critical care (London, England), 2008-01, Vol.12 Suppl 6 (Suppl 6), p.S4-S4

Laterre, Pierre-Francois

2008

Volltextzugriff (PDF)

Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock

Critical care (London, England), 2010-01, Vol.14 (4), p.R126-R126

2010

Volltextzugriff (PDF)

Serum uric acid, disease severity and outcomes in COVID-19

Critical care (London, England), 2021-06, Vol.25 (1), p.1-212, Article 212

2021

Volltextzugriff (PDF)

Severe community acquired pneumonia update: mortality, mechanisms and medical intervention

Critical care (London, England), 2008-01, Vol.12 Suppl 6 (Suppl 6), p.S1-S1

Laterre, Pierre-Francois

2008

Volltextzugriff (PDF)

Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial

Critical care (London, England), 2012-01, Vol.16 (1), p.R14-R14

2012

Volltextzugriff (PDF)

Passive leg cycling and electrical stimulation cannot preserve strength in sepsis

Critical care (London, England), 2019-02, Vol.23 (1), p.37-2, Article 37

2019

Volltextzugriff (PDF)

Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock

Critical care (London, England), 2010-01, Vol.14 (2), p.R53-R53

2010

Volltextzugriff (PDF)

Current practices and barriers impairing physicians' and nurses' adherence to analgo-sedation recommendations in the intensive care unit--a national survey

Critical care (London, England), 2014-12, Vol.18 (6), p.655-655, Article 655

2014

Volltextzugriff (PDF)

Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes

Critical care (London, England), 2014-01, Vol.18 (1), p.R17-R17

2014

Volltextzugriff (PDF)

Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational study

Critical care (London, England), 2011-01, Vol.15 (2), p.R88-R88

2011

Volltextzugriff (PDF)

Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)

Critical care (London, England), 2005-10, Vol.9 (5), p.R502-R507

2005

Volltextzugriff (PDF)

Clinical trials in severe sepsis with drotrecogin alfa (activated)

Critical care (London, England), 2007-01, Vol.11 Suppl 5 (Suppl 5), p.S5-S5

Laterre, Pierre-François

2007

Volltextzugriff (PDF)

A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia

Critical care (London, England), 2009-01, Vol.13 (2), p.R36-R36

2009

Volltextzugriff (PDF)

Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification

Critical care (London, England), 2003-12, Vol.7 (6), p.445-450

2003

Volltextzugriff (PDF)

Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis

Critical care (London, England), 2008-01, Vol.12 (5), p.R117-R117

2008

Volltextzugriff (PDF)

Selepressin, a novel selective vasopressin V 1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients

Critical care (London, England), 2017-08, Vol.21 (1), p.213

2017

Volltextzugriff (PDF)

Insufficient [beta]-lactam concentrations in the early phase of severe sepsis and septic shock

Critical care (London, England), 2010-07, Vol.14 (4), p.R126

2010

Volltextzugriff (PDF)

Insufficient b-lactam concentrations in the early phase of severe sepsis and septic shock

Critical care (London, England), 2010-07, Vol.14 (4), p.R126-R126

2010

Volltextzugriff (PDF)

Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes

Critical care (London, England), 2014-01, Vol.18 (1)

2014

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Aktive Filter

PublikationsformWebseiten

ThemaPatients

Zeitschrift / SerieCritical Care

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Critical Care Medicine
(20)
General & Internal Medicine
(20)
Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Humans
(18)
Female
(9)
Male
(9)
Middle Aged
(9)
Aged
(7)
Treatment Outcome
(7)
Prospective Studies
(6)
Sepsis - Drug Therapy
(6)
Adult
(5)
Protein C - Therapeutic Use
(5)
Recombinant Proteins - Therapeutic Use
(5)
Severity Of Illness Index
(5)
Critical Care
(4)
Health Aspects
(4)
Life Sciences
(4)
Pneumonia
(4)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(24)
Single Journals
(24)
Springer Nature - Complete Springer Journals
(24)
MEDLINE
(18)

Menü

Weitere Dienste

Einstellungen

A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients

The challenge of ventilator-associated pneumonia diagnosis in COVID-19 patients

Co-infections in COVID-19 critically ill and antibiotic management: a prospective cohort analysis

Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]

Determinants of long-term outcome in ICU survivors: results from the FROG-ICU study

Beyond antibiotics in severe community-acquired pneumonia: the role and rationale for tissue factor pathway inhibition

Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock

Serum uric acid, disease severity and outcomes in COVID-19

Severe community acquired pneumonia update: mortality, mechanisms and medical intervention

Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial

Passive leg cycling and electrical stimulation cannot preserve strength in sepsis

Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock

Current practices and barriers impairing physicians' and nurses' adherence to analgo-sedation recommendations in the intensive care unit--a national survey

Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes

Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational study

Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)

Clinical trials in severe sepsis with drotrecogin alfa (activated)

A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia

Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification

Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis

Selepressin, a novel selective vasopressin V 1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients

Insufficient [beta]-lactam concentrations in the early phase of severe sepsis and septic shock

Insufficient b-lactam concentrations in the early phase of severe sepsis and septic shock

Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes

Aktive Filter

Suchergebnisse filtern